[1]
Lim SA. Ethambutol-associated optic neuropathy. Annals of the Academy of Medicine, Singapore. 2006 Apr:35(4):274-8
[PubMed PMID: 16710500]
[2]
Palomino JC, Martin A. Drug Resistance Mechanisms in Mycobacterium tuberculosis. Antibiotics (Basel, Switzerland). 2014 Jul 2:3(3):317-40. doi: 10.3390/antibiotics3030317. Epub 2014 Jul 2
[PubMed PMID: 27025748]
[3]
Schubert K, Sieger B, Meyer F, Giacomelli G, Böhm K, Rieblinger A, Lindenthal L, Sachs N, Wanner G, Bramkamp M. The Antituberculosis Drug Ethambutol Selectively Blocks Apical Growth in CMN Group Bacteria. mBio. 2017 Feb 7:8(1):. doi: 10.1128/mBio.02213-16. Epub 2017 Feb 7
[PubMed PMID: 28174310]
[4]
Zhu C, Liu Y, Hu L, Yang M, He ZG. Molecular mechanism of the synergistic activity of ethambutol and isoniazid against Mycobacterium tuberculosis. The Journal of biological chemistry. 2018 Oct 26:293(43):16741-16750. doi: 10.1074/jbc.RA118.002693. Epub 2018 Sep 5
[PubMed PMID: 30185616]
[5]
Donald PR, Maher D, Maritz JS, Qazi S. Ethambutol dosage for the treatment of children: literature review and recommendations. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2006 Dec:10(12):1318-30
[PubMed PMID: 17167947]
[6]
Jeong I, Park JS, Cho YJ, Yoon HI, Song J, Lee CT, Lee JH. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels. Journal of Korean medical science. 2015 Feb:30(2):167-72. doi: 10.3346/jkms.2015.30.2.167. Epub 2015 Jan 21
[PubMed PMID: 25653488]
[7]
Bouffard MA, Nathavitharana RR, Yassa DS, Torun N. Re-Treatment With Ethambutol After Toxic Optic Neuropathy. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 2017 Mar:37(1):40-42. doi: 10.1097/WNO.0000000000000445. Epub
[PubMed PMID: 27636749]
[8]
Nemati E, Mokhtarzadeh A, Panahi-Azar V, Mohammadi A, Hamishehkar H, Mesgari-Abbasi M, Ezzati Nazhad Dolatabadi J, de la Guardia M. Ethambutol-Loaded Solid Lipid Nanoparticles as Dry Powder Inhalable Formulation for Tuberculosis Therapy. AAPS PharmSciTech. 2019 Feb 22:20(3):120. doi: 10.1208/s12249-019-1334-y. Epub 2019 Feb 22
[PubMed PMID: 30796625]
[9]
Geyer HL, Herskovitz S, Slamovits TL, Schaumburg HH. Optochiasmatic and peripheral neuropathy due to ethambutol overtreatment. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 2014 Sep:34(3):257-8. doi: 10.1097/WNO.0000000000000141. Epub
[PubMed PMID: 24897009]
[10]
Behera C, Krishna K, Singh HR. Antitubercular drug-induced violent suicide of a hospitalised patient. BMJ case reports. 2014 Jan 6:2014():. doi: 10.1136/bcr-2013-201469. Epub 2014 Jan 6
[PubMed PMID: 24395874]
Level 3 (low-level) evidence
[12]
Park JS, Lee JY, Lee YJ, Kim SJ, Cho YJ, Yoon HI, Lee CT, Song J, Lee JH. Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome. Antimicrobial agents and chemotherapy. 2016 Jan:60(1):92-8. doi: 10.1128/AAC.00693-15. Epub 2015 Oct 12
[PubMed PMID: 26459901]
[13]
Lounis N, Maslo C, Truffot-Pernot C, Grosset J, Boelaert RJ. Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2003 Jun:7(6):575-9
[PubMed PMID: 12797701]
[14]
Kim KL, Park SP. Visual function test for early detection of ethambutol induced ocular toxicity at the subclinical level. Cutaneous and ocular toxicology. 2016 Sep:35(3):228-32. doi: 10.3109/15569527.2015.1079784. Epub 2015 Sep 11
[PubMed PMID: 26361935]
[15]
Abbasi Nazari M, Kobarfard F, Tabarsi P, Salamzadeh J. Serum copper (cu) alterations in pulmonary tuberculosis patients under treatment with ethambutol. Biological trace element research. 2009 May:128(2):161-6. doi: 10.1007/s12011-008-8267-8. Epub 2008 Nov 11
[PubMed PMID: 19002388]
[16]
Kozak SF, Inderlied CB, Hsu HY, Heller KB, Sadun AA. The role of copper on ethambutol's antimicrobial action and implications for ethambutol-induced optic neuropathy. Diagnostic microbiology and infectious disease. 1998 Feb:30(2):83-7
[PubMed PMID: 9554173]
[17]
Chamberlain PD, Sadaka A, Berry S, Lee AG. Ethambutol optic neuropathy. Current opinion in ophthalmology. 2017 Nov:28(6):545-551. doi: 10.1097/ICU.0000000000000416. Epub
[PubMed PMID: 28759559]
Level 3 (low-level) evidence
[18]
Valencia S, León M, Losada I, Sequera VG, Fernández Quevedo M, García-Basteiro AL. How do we measure adherence to anti-tuberculosis treatment? Expert review of anti-infective therapy. 2017 Feb:15(2):157-165. doi: 10.1080/14787210.2017.1264270. Epub 2016 Dec 20
[PubMed PMID: 27910715]